Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Non-Current Debt (2018 - 2026)

TransMedics has reported Non-Current Debt over the past 8 years, most recently at $49.6 million for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 16.48% year-over-year to $49.6 million; the TTM value through Dec 2025 reached $49.6 million, down 16.48%, while the annual FY2025 figure was $49.6 million, 16.48% down from the prior year.
  • Non-Current Debt for Q4 2025 was $49.6 million at TransMedics, down from $54.6 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $59.5 million in Q2 2025 and troughed at $34.8 million in Q1 2021.
  • A 5-year average of $51.2 million and a median of $58.7 million in 2022 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: surged 66.98% in 2022 and later fell 16.48% in 2025.
  • Year by year, Non-Current Debt stood at $35.2 million in 2021, then skyrocketed by 66.76% to $58.7 million in 2022, then increased by 0.63% to $59.1 million in 2023, then increased by 0.52% to $59.4 million in 2024, then dropped by 16.48% to $49.6 million in 2025.
  • Business Quant data shows Non-Current Debt for TMDX at $49.6 million in Q4 2025, $54.6 million in Q3 2025, and $59.5 million in Q2 2025.